AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.
The company impresses investors, but money’s running short.
Menin, BTK and a Car-T skirmish featured over the ASH weekend.
But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
